Page 25 - Serum Institute Of India

Delighted at AstraZeneca vaccine's effectiveness: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Monday expressed happiness at pharma major AstraZeneca's announcement that its COVID-19 vaccine candidate has been found to be 70 per cent effective on average. AstraZeneca said one dosing regimen showed vaccine efficacy of 90 per cent when the vaccine was given as a half-dose followed by a full dose at least one month apart, while another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart. "The combined analysis from both dosing regimens resulted in an average efficacy of 70 per cent," it added. In a tweet, Poonawalla said, "I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime...". SII is currently conducting clinical trials of Oxford University-AstraZeneca's COVID-19 vaccine candidate in India. AstraZeneca also ...

Serum's Covid vaccine deadline, high-level teams sent to 4 states, & more

The vaccine developers are slowly, but surely are accepting the reality of not meeting the estimated targets in producing shots

Pfizer vaccine's -70 degree storage norm tough for most nations: V K Paul

Limited number of doses would not be enough to meet India's demand, adds Niti Aayog member

Top headlines: Govt expands stimulus, Moody's raises India GDP forecast

From govt announcing fresh stimulus aimed at creating jobs to TCS acquiring Pramerica Tech Services, Business Standard brings you the top headlines of the day

ICMR-Serum Institute Covid vaccine completes enrolment for phase 3 trials

ICMR and SII have further collaborated for the clinical development of COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII

Govt may allow use of Covid vaccine in emergency situations: Harsh Vardhan

Warns of spike in cases during winter; China, UAE among the few countries have allowed such authorisation

Repurposing capacity for Covid-19 vaccine, say Indian pharma firms

Suresh Jadhav, executive director of the Serum Institute of India (SII), said the biotechnology company has already put in place an expansion plan for new products in the pipeline

Serum Institute to make 100 mn more doses of Covid vaccine for Rs 250 each

Secures additional $150 mn risk funding from Bill and Melinda Gates Foundation

Serum Institute to make an additional 100 million Covid-19 vaccine doses

BENGALURU (Reuters) - Serum Institute of India said on Tuesday it would get a further $150 million in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make an additional 100 million COVID-19 vaccine doses for India and other low- and middle-income countries next year.

ICMR launches a new vaccine portal for Covid, with details of trials

The portal covers other ailments as well; will provide details of progress made locally and globally at regular intervals

Does govt have Rs 80,000 cr to buy, give out vaccine, Serum Inst chief asks

Experts say even as vaccine is being developed, govt should put in place its strategy for distribution and procurement instead of waiting for the vaccine to be ready

Serum Institute starts manufacturing Codagenix's potential Covid-19 vaccine

Serum Institute, the world's largest vaccine maker by number of doses produced, will develop Codagenix's CDX-005, which is delivered intranasally rather than via an injection

Oxford vaccine: Phase-3 trial to begin in Pune next week, volunteers enrol

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city

Serum Institute of India gets nod to resume Covid-19 vaccine trial

The resumption of trails was allowed after the vaccine maker submitted recommendations of the Data Safety Monitoring Board (DSMB), the UK, and DSMB, India

Delivering Covid vaccine a governance challenge, India should take lead

One critical challenge will be storage and transportation. Some of the vaccines that use the new messenger RNA technology will need to be stored at subzero temperatures

Serum Institute gets DCGI nod to resume clinical trial of Oxford vaccine

DCGI gave permission to Serum Institute to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country

Novavax, Serum Institute to produce 2 bn Covid vaccine doses under new deal

The U.S. company's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus

Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla

Poonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two steps

DCGI aks Serum Institute to suspend recruitment for Oxford vaccine trials

DCGI has directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India